secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aprea Therapeutics, Inc. (APRE)
CIK:        0001781983
Form:       8-K
Filed at:   2023-01-30T23:59:59+00:00
Accession:  0001104659-23-008020
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aprea Therapeutics appoints John Hamill as CFO, replacing Scott Coiante
-----------------------------------------------------------------------

- John Hamill appointed CFO effective Jan 30, 2023; succeeds Scott Coiante who remains through March 31.
- Hamill brings over 30 years finance experience; previously CFO at Windtree Therapeutics, Trevena, NephroGenex.
- Compensation: $420k base salary, 40% target bonus, $50k sign-on bonus (payable March 2024).
- Equity grant: options for 539,758 shares (4-year vest) and RSUs for 269,879 shares (3-year vest).
- Coiante receives 12 months base salary and health benefits under separation agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781983/000110465923008020/0001104659-23-008020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781983/000110465923008020/tm234708d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-008020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer